NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 11/6/2026

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Advanced

Key Stats

Today's Range
$40.00
▼
$40.00
50-Day Range
$40.00
▼
$40.00
52-Week Range
$15.25
▼
$43.00
Volume
N/A
Average Volume
10,339 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Calliditas Therapeutics AB (publ) is a Swedish biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Founded in 2004 and headquartered in Stockholm, the company has concentrated on therapies for kidney and liver conditions.

Its main product is a targeted-release formulation of budesonide, marketed as Tarpeyo in the United States and Kinpeygo in Europe. The treatment is approved for adults with primary IgA nephropathy, a rare kidney disease. Calliditas has also developed other investigational therapies, including setanaxib.

Calliditas served markets in North America and Europe and was acquired by Japan-based Asahi Kasei in 2024, after which its shares ceased trading on Nasdaq.

AI Generated. May Contain Errors.

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CALT Stock News Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Headlines

CALT Stock Analysis - Frequently Asked Questions

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 on January 1st, 2026. Since then, CALT stock has increased by 0.0% and is now trading at $40.0001.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.09. The business earned $52.36 million during the quarter, compared to analyst estimates of $42.89 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 212.04% and a negative net margin of 30.18%.
Read the conference call transcript
.

Calliditas Therapeutics AB (publ) (CALT) raised $81 million in an IPO on Friday, June 5th 2020. The company issued 4,153,385 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Upstart (UPST), DigitalOcean (DOCN), Lemonade (LMND), Appian (APPN), NVIDIA (NVDA), Outset Medical (OM) and Atea Pharmaceuticals (AVIR).

Company Calendar

Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CALT
CIK
1795579
Fax
N/A
Employees
180
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($1.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
8.68
P/E Growth
N/A
Net Income
-$43.96 million
Net Margins
-30.18%
Pretax Margin
-29.40%
Return on Equity
-212.04%
Return on Assets
-27.96%

Debt

Debt-to-Equity Ratio
9.44
Current Ratio
2.69
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$1.60 billion
Price / Sales
0.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.06 per share
Price / Book
37.74

Miscellaneous

Outstanding Shares
29,790,000
Free Float
29,135,000
Market Cap
$1.19 billion
Optionable
No Data
Beta
1.77

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:CALT) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners